EMEA Point-Of-Care Diagnostics Market Size, Share, Trends, Industry Analysis Report: By Product, End Use (Clinics, Hospitals, Home, Assisted Living Healthcare Facilities, Laboratory, and Others), and Region (Europe, and Middle East & Africa) – Market Fore
Description
The global EMEA point-of-care diagnostics market size is expected to reach USD 22.66 billion by 2034, according to a new study by Polaris Market Research. The report “EMEA Point-Of-Care Diagnostics Market Share, Size, Trends, Industry Analysis Report: By Product, End Use (Clinics, Hospitals, Home, Assisted Living Healthcare Facilities, Laboratory, and Others), and Region (Europe, and Middle East & Africa); Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Point-of-care (POC) diagnostics refer to rapid medical testing conducted at or near the site of patient care, allowing timely clinical decision-making. A major trend shaping the EMEA point-of-care diagnostics market development is the increasing integration of digital health technologies, such as artificial intelligence (AI) and cloud-based data analytics. These advancements improve diagnostic accuracy, allow real-time monitoring, and facilitate seamless data sharing between patients and healthcare providers. The growing adoption of connected POC devices supports personalized treatment approaches and improves overall healthcare efficiency. The demand for technologically advanced POC solutions is expected to rise as healthcare systems continue to adopt digital transformation.
Another major trend driving the EMEA point-of-care diagnostics market growth is the shift toward decentralized healthcare, highlighting accessibility and convenience in diagnostic testing. The rising prevalence of chronic and infectious diseases has heightened the need for rapid, on-site testing solutions that reduce dependency on centralized laboratories. POC diagnostics play a critical role in improving early disease detection and patient management, particularly in resource-limited settings. The expansion of home-based and community healthcare models further accelerates the demand for portable and user-friendly diagnostic devices. The adoption of decentralized POC testing is expected to expand, with healthcare providers focusing on improving patient-centric care.
EMEA Point-Of-Care Diagnostics Market Report Highlights
In terms of product, the glucose testing segment led the EMEA point-of-care diagnostics market in 2024, driven by the high prevalence of diabetes and the increasing demand for continuous glucose monitoring solutions.
Based on end use, the home segment is anticipated to experience the fastest growth during the forecast period, fueled by the rising trend toward decentralized, patient-centric healthcare models.
Germany dominated the EMEA point-of-care diagnostics market revenue in 2024, supported by its advanced healthcare infrastructure, high healthcare spending, and the strong presence of key industry players.
The UK is projected to witness the fastest growth in the EMEA point-of-care diagnostics market, driven by increased investments in digital healthcare and a strong focus on decentralized diagnostic solutions.
A few global key market players include Abbott; BD; BIOMÉRIEUX; Danaher Corporation; F. Hoffmann-La Roche Ltd; Nova Biomedical; QIAGEN; Siemens Healthcare Private Limited; Trividia Health, Inc.; and Werfen.
Polaris Market Research has segmented the EMEA point-of-care diagnostics market report on the basis of product, end use, and region:
By Product Outlook (Revenue, USD Billion, 2020–2034)
Glucose Testing
Hb1Ac Testing
Coagulation Testing
Fertility/Pregnancy
Infectious Disease, including HIV POC
Cancer Makers
Others
By End Use Outlook (Revenue, USD Billion, 2020–2034)
Clinics
Hospitals
Home
Assisted Living Healthcare Facilities
Laboratory
Others
By Regional Outlook ((Revenue, USD Billion, 2020–2034)
Europe
Point-of-care (POC) diagnostics refer to rapid medical testing conducted at or near the site of patient care, allowing timely clinical decision-making. A major trend shaping the EMEA point-of-care diagnostics market development is the increasing integration of digital health technologies, such as artificial intelligence (AI) and cloud-based data analytics. These advancements improve diagnostic accuracy, allow real-time monitoring, and facilitate seamless data sharing between patients and healthcare providers. The growing adoption of connected POC devices supports personalized treatment approaches and improves overall healthcare efficiency. The demand for technologically advanced POC solutions is expected to rise as healthcare systems continue to adopt digital transformation.
Another major trend driving the EMEA point-of-care diagnostics market growth is the shift toward decentralized healthcare, highlighting accessibility and convenience in diagnostic testing. The rising prevalence of chronic and infectious diseases has heightened the need for rapid, on-site testing solutions that reduce dependency on centralized laboratories. POC diagnostics play a critical role in improving early disease detection and patient management, particularly in resource-limited settings. The expansion of home-based and community healthcare models further accelerates the demand for portable and user-friendly diagnostic devices. The adoption of decentralized POC testing is expected to expand, with healthcare providers focusing on improving patient-centric care.
EMEA Point-Of-Care Diagnostics Market Report Highlights
In terms of product, the glucose testing segment led the EMEA point-of-care diagnostics market in 2024, driven by the high prevalence of diabetes and the increasing demand for continuous glucose monitoring solutions.
Based on end use, the home segment is anticipated to experience the fastest growth during the forecast period, fueled by the rising trend toward decentralized, patient-centric healthcare models.
Germany dominated the EMEA point-of-care diagnostics market revenue in 2024, supported by its advanced healthcare infrastructure, high healthcare spending, and the strong presence of key industry players.
The UK is projected to witness the fastest growth in the EMEA point-of-care diagnostics market, driven by increased investments in digital healthcare and a strong focus on decentralized diagnostic solutions.
A few global key market players include Abbott; BD; BIOMÉRIEUX; Danaher Corporation; F. Hoffmann-La Roche Ltd; Nova Biomedical; QIAGEN; Siemens Healthcare Private Limited; Trividia Health, Inc.; and Werfen.
Polaris Market Research has segmented the EMEA point-of-care diagnostics market report on the basis of product, end use, and region:
By Product Outlook (Revenue, USD Billion, 2020–2034)
Glucose Testing
Hb1Ac Testing
Coagulation Testing
Fertility/Pregnancy
Infectious Disease, including HIV POC
Cancer Makers
Others
By End Use Outlook (Revenue, USD Billion, 2020–2034)
Clinics
Hospitals
Home
Assisted Living Healthcare Facilities
Laboratory
Others
By Regional Outlook ((Revenue, USD Billion, 2020–2034)
Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
Table of Contents
129 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. EMEA Point-Of-Care Diagnostics Market Insights
- 4.1. EMEA Point-Of-Care Diagnostics Market – Market Snapshot
- 4.2. EMEA Point-Of-Care Diagnostics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Demand for Home Healthcare
- 4.2.1.2. Rising Focus on Personalized Medicine
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Rigid regulatory approval process
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. EMEA Point-Of-Care Diagnostics Market Trends
- 4.6. Value Chain Analysis
- 5. EMEA Point-Of-Care Diagnostics Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 5.3. Glucose Testing
- 5.3.1. EMEA Point-Of-Care Diagnostics Market, by Glucose Testing, by Region, 2020-2034 (USD Billion)
- 5.4. Hb1Ac Testing
- 5.4.1. EMEA Point-Of-Care Diagnostics Market, by Hb1Ac Testing, by Region, 2020-2034 (USD Billion)
- 5.5. Coagulation Testing
- 5.5.1. EMEA Point-Of-Care Diagnostics Market, by Coagulation Testing, by Region, 2020-2034 (USD Billion)
- 5.6. Fertility/Pregnancy
- 5.6.1. EMEA Point-Of-Care Diagnostics Market, by Fertility/Pregnancy, by Region, 2020-2034 (USD Billion)
- 5.7. Infectious Disease, Including HIV POC
- 5.7.1. EMEA Point-Of-Care Diagnostics Market, by Infectious Disease, Including HIV POC, by Region, 2020-2034 (USD Billion)
- 5.8. Cancer Makers
- 5.8.1. EMEA Point-Of-Care Diagnostics Market, by Cancer Makers, by Region, 2020-2034 (USD Billion)
- 5.9. Others
- 5.9.1. EMEA Point-Of-Care Diagnostics Market, by Others, by Region, 2020-2034 (USD Billion)
- 6. EMEA Point-Of-Care Diagnostics Market, by End Use
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 6.3. Clinics
- 6.3.1. EMEA Point-Of-Care Diagnostics Market, by Clinics, by Region, 2020-2034 (USD Billion)
- 6.4. Hospitals
- 6.4.1. EMEA Point-Of-Care Diagnostics Market, by Hospitals, by Region, 2020-2034 (USD Billion)
- 6.5. Home
- 6.5.1. EMEA Point-Of-Care Diagnostics Market, by Home, by Region, 2020-2034 (USD Billion)
- 6.6. Assisted Living Healthcare Facilities
- 6.6.1. EMEA Point-Of-Care Diagnostics Market, by Assisted Living Healthcare Facilities, by Region, 2020-2034 (USD Billion)
- 6.7. Laboratory
- 6.7.1. EMEA Point-Of-Care Diagnostics Market, by Laboratory, by Region, 2020-2034 (USD Billion)
- 6.8. Others
- 6.8.1. EMEA Point-Of-Care Diagnostics Market, by Others, by Region, 2020-2034 (USD Billion)
- 7. EMEA Point-Of-Care Diagnostics Market, by Geography
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. EMEA Point-Of-Care Diagnostics Market Assessment, By Geography, 2020-2034 (USD Billion)
- 7.3. EMEA Point-Of-Care Diagnostics Market – Europe
- 7.3.1. Europe: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.3.2. Europe: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 7.3.3. EMEA Point-Of-Care Diagnostics Market – UK
- 7.3.3.1. UK: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.3.3.2. UK: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 7.3.4. EMEA Point-Of-Care Diagnostics Market – France
- 7.3.4.1. France: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.3.4.2. France: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 7.3.5. EMEA Point-Of-Care Diagnostics Market – Germany
- 7.3.5.1. Germany: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.3.5.2. Germany: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 7.3.6. EMEA Point-Of-Care Diagnostics Market – Italy
- 7.3.6.1. Italy: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.3.6.2. Italy: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 7.3.7. EMEA Point-Of-Care Diagnostics Market – Spain
- 7.3.7.1. Spain: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.3.7.2. Spain: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 7.3.8. EMEA Point-Of-Care Diagnostics Market – Netherlands
- 7.3.8.1. Netherlands: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.3.8.2. Netherlands: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 7.3.9. EMEA Point-Of-Care Diagnostics Market – Russia
- 7.3.9.1. Russia: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.3.9.2. Russia: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 7.3.10. EMEA Point-Of-Care Diagnostics Market – Rest of Europe
- 7.3.10.1. Rest of Europe: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.3.10.2. Rest of Europe: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 7.4. EMEA Point-Of-Care Diagnostics Market – Middle East & Africa
- 7.4.1. Middle East & Africa: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.4.2. Middle East & Africa: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 7.4.3. EMEA Point-Of-Care Diagnostics Market – Saudi Arabia
- 7.4.3.1. Saudi Arabia: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.4.3.2. Saudi Arabia: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 7.4.4. EMEA Point-Of-Care Diagnostics Market – UAE
- 7.4.4.1. UAE: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.4.4.2. UAE: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 7.4.5. EMEA Point-Of-Care Diagnostics Market – Israel
- 7.4.5.1. Israel: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.4.5.2. Israel: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 7.4.6. EMEA Point-Of-Care Diagnostics Market – South Africa
- 7.4.6.1. South Africa: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.4.6.2. South Africa: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 7.4.7. EMEA Point-Of-Care Diagnostics Market – Rest of Middle East & Africa
- 7.4.7.1. Rest of Middle East & Africa: EMEA Point-Of-Care Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 7.4.7.2. Rest of Middle East & Africa: EMEA Point-Of-Care Diagnostics Market, by End Use, 2020-2034 (USD Billion)
- 8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
- 9. Company Profiles
- 9.1. Abbott
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. BD
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. BIOMÉRIEUX
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Danaher Corporation
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. F. Hoffmann-La Roche Ltd
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Nova Biomedical
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. QIAGEN
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Siemens Healthcare Private Limited
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Trividia Health, Inc.
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Werfen
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
